Cargando…

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model

BACKGROUND: Levodopa (L‐DOPA) is considered the most reliable drug for treating Parkinson's disease (PD) clinical symptoms. Regrettably, long‐term L‐DOPA therapy results in the emergence of drug‐induced abnormal involuntary movements (AIMs) in most PD patients. The mechanisms underlying motor f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kambey, Piniel Alphayo, Liu, Wen Ya, Wu, Jiao, Tang, Chuanxi, Buberwa, Wokuheleza, Saro, Adonira, Nyalali, Alphonce M. K., Gao, Dianshuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493657/ https://www.ncbi.nlm.nih.gov/pubmed/37101388 http://dx.doi.org/10.1111/cns.14229

Ejemplares similares

Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review
por: Kambey, Piniel Alphayo, et al.
Publicado: (2021)

HIV-1 gp120 Protein Activates Cyclin-Dependent Kinase 1, a Possible Link to Central Nervous System Cell Death
por: Saro, Adonira, et al.
Publicado: (2022)

Extracellular and Intracellular Factors in Brain Cancer
por: Kanwore, Kouminin, et al.
Publicado: (2021)

Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma
por: Kanwore, Kouminin, et al.
Publicado: (2022)

Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
por: Zhang, SuFang, et al.
Publicado: (2014)

Doublecortin undergo nucleocytoplasmic transport via the RanGTPase signaling to promote glioma progression
por: Ayanlaja, Abiola Abdulrahman, et al.
Publicado: (2020)

Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson’s disease associated with nuclear receptor-related factor 1 defect
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu, Na, et al.
Publicado: (2018)

Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
por: Wang, Wen-Wen, et al.
Publicado: (2019)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Carnosic Acid Alleviates Levodopa-Induced Dyskinesia and Cell Death in 6-Hydroxydopamine-lesioned Rats and in SH-SY5Y Cells
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Lower GDNF Serum Level Is a Possible Risk Factor for Constipation in Patients With Parkinson Disease: A Case–Control Study
por: Chen, Gang, et al.
Publicado: (2022)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Involvement of Autophagy in Levodopa‐Induced Dyskinesia
por: Feyder, Michael, et al.
Publicado: (2021)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways
por: Cheng, Bo, et al.
Publicado: (2022)

Correction: Cheng et al. Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways. Cells 2022, 11, 3232
por: Cheng, Bo, et al.
Publicado: (2023)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
por: Zheng, Chang-Qing, et al.
Publicado: (2021)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
por: Herz, Damian M., et al.
Publicado: (2016)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
por: Li, Michael H., et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: König, Eva, et al.
Publicado: (2021)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
por: Youn, Jinyoung, et al.
Publicado: (2022)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
por: Bispo, Ana Gabrielle, et al.
Publicado: (2023)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease
por: Tang, Chuan-Xi, et al.
Publicado: (2022)

Testosterone upregulates glial cell line-derived neurotrophic factor (GDNF) and promotes neuroinflammation to enhance glioma cell survival and proliferation
por: Kanwore, Kouminin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_65ms85r9af5gc7nim9us9d88qg